Biopharma Watch: Low Float (Nasdaq: DMAC) Hits Our Radar With 5 Key Potential Catalysts

Monday's profile turned into a strong little runner.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Biopharma Watch: Low Float (Nasdaq: DMAC) Hits Our Radar With 5 Key Potential Catalysts *Click Here To Get Our Alerts Faster Via SMS* June 16th Dear Reader, Monday's profile turned into a strong little runner. Popping from an open of $1.28 to a high of $1.43+, it ran approx. 12% intraday while kicking the week off in solid fashion. Now, let's turn our focus to a growing market ripe for disruption. Already valued at over $1Bn since 2024, the the global preeclampsia market size is expected to reach $2.73Bn by 2033. Following the reception of a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate their lead therapy in patients with early-onset preeclampsia, one under-the-radar company has shared key plans to initiate a Phase 2 trial in 2026. But before that trial gets the chance to kick off, we're putting this Nasdaq idea at the top of our watchlist: DiaMedica Therapeutics Inc. (Nasdaq: DMAC) DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. And based on multiple potential catalysts, (Nasdaq: DMAC) has climbed to our top watchlist spot for Tuesday. Take a look: #1. An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit). #2. A 75% Enrollment Milestone Is Notched In The Company's ReMEDy2 Phase 2/3 Trial. #3. Health Canada Clearance Helps Pave The Way For The Company To Initiate Key Phase 2 Study. #4. Company Visibility Could Be Getting Kicked Into Overdrive After Attending Multiple Conferences. #5. The Size Of This Float May Create A Potential Environment For Heightened Volatility. But more on those in a second... Intended to Restore Natural, Healthy Function DiaMedica’s lead candidate, DM199 (rhKLK1), is a recombinant form of the human tissue KLK1 protein which enhances blood flow and vascular health by increasing the available levels of nitric oxide (NO), prostacyclin (PGI2), and endothelium-derived hyperpolarizing factor (EDHF). Through this novel mechanism of action, DM199 has the potential to modify disease progression in preeclampsia and fetal growth restriction and enhance collateral circulation in acute ischemic stroke. DM199: Lead Program Positioned to Drive Near- and Mid-Term Value Recombinant human KLK1 protein for vascular and ischemic diseases Preeclampsia (PE) and Fetal Growth Restriction (FGR) Ongoing Phase 2 PE Basket Trial Increase blood flow to placenta and reduce blood pressure and endothelial dysfunction Positive Phase 2 interim results: significantly lowered blood pressure and reduced uterine artery resistance with encouraging safety and tolerability, and importantly, no placental transfer Global Phase 2 in early-onset PR expected to initiate in late 2026 FGR cohort anticipated to start in 2Q 2026 Estimated $5Bn+ U.S. market opp. Growth Restriction (FGR) Acute Ischemic Stroke (AIS) Enrolling Phase 2/3 Trial Mechanism designed to increase collateral circulation in the ischemic penumbra following stroke Phase 2 data demonstrated clinically meaningful outcomes in AIS patients treated within a 24-hour treatment window >75% enrollment achieved Estimated $10Bn+ U.S. market opp. Well-capitalized with multiple mid-term value catalysts Funded Through Multiple Expected Clinical Catalysts Preeclampsia and FGR: 5 phase readouts expected between 2Q 2026 and end of 2027 Acute ischemic stroke: ReMEDy2 Phase 2/3 AIS interim analysis planned in 2H 2026 $51Mn (as of March 31st, 2026) cash provides runway through 2H 2027 (no warrants or debt) DM199 for Pregnancy Complications Controlling Blood Pressure and Improving Overall Endothelial Health DM199 (rhKLK1) is an investigational therapy designed to improve endothelial health and support blood pressure regulation and placental perfusion in preeclampsia and fetal growth restriction. By activating natural vasodilation pathways, DM199 aims to address both maternal and fetal complications associated with vascular dysfunction, with the goal of improving outcomes for mother and baby. A Novel Mechanism to Modify Disease DM199 treatment is intended to counterbalance the evolution of PE by triggering the natural release of endothelial NO, PGI2, and EDHF. The activation of these signaling pathways, as was seen in the interim results of DiaMedica’s investigator sponsored PE trial, is believed to promote the vasodilation of blood vessels, and as a result, reduce maternal blood pressure, enhance placental blood flow and improve endothelial health. Additionally, clinical data demonstrate that DM199 does not cross the placental barrier, a significant safety advantage. In PE, DM199 is the only therapy in development simultaneously targeting maternal hemodynamics and fetal outcomes including FGR. Potential Benefits of DM199 for Preeclampsia & Fetal Growth Restriction Lower Blood Pressure • Improve Endothelial Health • Increase Maternal Organ Perfusion • Dilate Intrauterine Arteries Clinical Studies DiaMedica is collaborating with world leaders from Stellenbosch University, the University of Melbourne, and the University of Gothenburg who are conducting an investigator-sponsored trial. The interim Part 1a results are highly encouraging and demonstrate the best-in-class potential of DM199 as an effective therapeutic for preeclampsia. DM199 exhibited a favorable safety profile, with no placental transfer and no serious treatment-emergent adverse events reported. DM199 also produced clinically meaningful and statistically significant, dose-dependent reductions in both systolic and diastolic blood pressure across multiple timepoints.  Additionally, DM199 achieved a statistically significant improvement in uterine artery pulsatility index at the 2-hour assessment, indicating its potential for enhanced placental perfusion and disease modification. DM199 for Acute Ischemic Stroke Potential to Treat More Stroke Patients The company's investigational drug product candidate, DM199 (rhKLK1), aims to preserve valuable brain tissue during the hours to weeks after an acute ischemic stroke by promoting collateral circulation in the ischemic penumbra. DM199 is being clinically studied with treatment initiated up to 24 hours after the onset of stroke symptoms, a treatment window five times longer than any existing therapeutic.  DM199, a synthetic version of the naturally occurring KLK1 protein, may provide a safer alternative treatment for a wider range of stroke patients. A Mechanism to Enhance Collateral Circulation DM199 (rhKLK1), as demonstrated in the graphics below, is intended to increase production of bradykinin which in turn activates a greater number of the increased bradykinin 2 receptors present in the arteries affected by the AIS, referred to as the ischemic penumbra, thus improving collateral circulation in the ischemic penumbra. By delivering vital oxygen and nutrients to brain tissues in need, DM199 may preserve/restore neuronal function and reduce the size of the ischemic penumbra, minimizing neuronal cell death (infarction) and brain damage. DiaMedica Therapeutics Pipeline Report Sources And More Here: DMAC Website. DMAC Presentation. ----- And as we mentioned above, (Nasdaq: DMAC) has multiple potential catalysts on our radar. Check them out: #1. DMAC Potential Catalyst - An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit). Check out what MarketBeat is reporting: As of Monday's close, DMAC had 6 analyst targets pointing to a significant amount of upside potential. In fact, with an average target of $12.33, DMAC could have over 119% potential upside from its closing valuation on the 15th. Could these targets suggest that (Nasdaq: DMAC) is undervalued from current chart levels? ----- #2. DMAC Potential Catalyst - A 75% Enrollment Milestone Is Notched In The Company's ReMEDy2 Phase 2/3 Trial. DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim Analysis Interim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging Between 300 and 728 Patients) is Recommended Interim Analysis Anticipated to be Completed Before Year-End 2026 MINNEAPOLIS, May 20, 2026--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the 200-patient threshold required to trigger the planned interim analysis. The Company reiterates its guidance regarding completion of the interim analysis by the end of 2026. ... "Reaching 75% enrollment toward our interim analysis threshold is a meaningful milestone that reflects the dedication of our clinical sites and the urgency of finding new treatments for stroke patients," said Dr. Julie Krop, Chief Medical Officer of DiaMedica Therapeutics. "We now have approximately 70 sites activated. Based on projected enrollment rates across our network of centers in the United States, Canada, the United Kingdom and Europe, we anticipate completing the interim analysis before year-end. This analysis will be an important inflection point for the program, providing critical data to guide the path forward for DM199 in acute ischemic stroke." Read the full article here. ----- #3. DMAC Potential Catalyst - Health Canada Clearance Helps Pave The Way For The Company To Initiate Key Phase 2 Study. DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia "No Objection Letter" from Health Canada enables initiation of Phase 2 DM199 study in early-onset preeclampsia DM199 Preeclampsia program featured in recent National Public Radio (NPR) coverage MINNEAPOLIS, March 05, 2026--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase 2 trial in patients with early-onset preeclampsia (PE). This regulatory clearance enables DiaMedica to initiate its Phase 2 study of DM199 in early-onset preeclampsia. The Company plans to initiate the trial in 2026 and expand into the United States and United Kingdom as regulatory clearances are obtained. "Health Canada's authorization to initiate our Phase 2 clinical trial of DM199 in preeclampsia represents an important regulatory milestone for DiaMedica," said Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics. "This clearance allows us to launch our planned Phase 2 PE study to build upon the encouraging results observed in the investigator-sponsored trial in South Africa. We look forward to continuing our work to bring a clinically meaningful therapeutic option for women suffering from early-onset preeclampsia, a patient population with significant unmet medical need and no currently approved treatment options." ... Read the full article here. ----- #4. DMAC Potential Catalyst - Company Visibility Could Be Getting Kicked Into Overdrive After Attending Multiple Conferences. In the last several months, DMAC has been on the move participating in multiple conferences that could drive company visibility. Look at these: 1.) DiaMedica Therapeutics to Present at the Jefferies Global Heal-thcare Conference 2026 2.) DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Heal-thcare Conference 3.) RedChip's April 16 Virtual In-vest-or Conference to Feature Companies Advancing Clinical Pipelines and Scalable Heal-thcare Platforms 4.) DiaMedica Therapeutics to Participate in Upcoming March In-vest-or Conferences ----- #5. DMAC Potential Catalyst - The Size Of This Float May Create A Potential Environment For Heightened Volatility. According to info from the Yahoo Finance website, DMAC has a relatively low float. The website reports this profile to have roughly 28.77Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides positive news during the first half of 2026, could it help provide a breakout spark when paired with this volatility potential? ----- (Nasdaq: DMAC) Recap - These 5 Potential Catalysts Hit Our Radar #1. An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit). #2. A 75% Enrollment Milestone Is Notched In The Company's ReMEDy2 Phase 2/3 Trial. #3. Health Canada Clearance Helps Pave The Way For The Company To Initiate Key Phase 2 Study. #4. Company Visibility Could Be Getting Kicked Into Overdrive After Attending Multiple Conferences. #5. The Size Of This Float May Create A Potential Environment For Heightened Volatility. ----- We're initiating coverage on DiaMedica Therapeutics Inc. (Nasdaq: DMAC). Be on the lookout for updates coming out soon. Talk again shortly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 06/15/2026 and ending on 06/16/2026 to publicly disseminate information about (DMAC:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the seventeen thousand five hundred USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (DMAC:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/dmac-rglzm/#details

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice